Authors: Naeger, LK Margot, NA Miller, MD

Citation: Lk. Naeger et al., Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudine, NUCLEOS NUC, 20(4-7), 2001, pp. 635-639

Authors: Miller, MD Margot, NA Hertogs, K Larder, B Miller, V

Citation: Md. Miller et al., Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples, NUCLEOS NUC, 20(4-7), 2001, pp. 1025-1028

Authors: Miller, MD Margot, NA Lamy, PD Fuller, MD Anton, KE Mulato, AS Cherrington, JM

Citation: Md. Miller et al., Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: Genotypic and phenotypic analyses of study GS-96-408, J ACQ IMM D, 27(5), 2001, pp. 450-458

Authors: Naeger, LK Margot, NA Miller, MD

Citation: Lk. Naeger et al., Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication, ANTIVIR TH, 6(2), 2001, pp. 115-126

Authors: Van Rompay, KKA Miller, MD Marthas, ML Margot, NA Dailey, PJ Canfield, DR Tarara, RP Cherrington, JM Aguirre, NL Bischofberger, N Pedersen, NC

Citation: Kka. Van Rompay et al., Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA, J VIROLOGY, 74(4), 2000, pp. 1767-1774

Authors: Wainberg, MA Miller, MD Quan, YD Salomon, H Mulato, AS Lamy, PD Margot, NA Anton, KE Cherrington, JM

Citation: Ma. Wainberg et al., In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA, ANTIVIR TH, 4(2), 1999, pp. 87-94